Publication:
Patterns of hydroxyurea prescription and use in routine clinical management of polycythemia vera: A multicenter chart review study

dc.contributor.authorBüyükaşık, Yahya
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorSaydam, Güray
dc.contributor.authorYavuz, Selim
dc.contributor.authorÜnal, Ali
dc.contributor.authorAr, Muhlis Cem
dc.contributor.authorAyyıldız, Orhan
dc.contributor.authorAltuntaş, Fevzi
dc.contributor.authorOkay, Mufide
dc.contributor.authorÇiftçiler, Rafiye
dc.contributor.authorMeletli, Özgür
dc.contributor.authorSoyer, Nur
dc.contributor.authorMastanzade, Metban
dc.contributor.authorGüven, Zeynep
dc.contributor.authorSoysal, Teoman
dc.contributor.authorKarakuş, Abdullah
dc.contributor.authorYiğenoğlu, Tuğce Nur
dc.contributor.authorUçar, Barış
dc.contributor.authorGökçen, Ece
dc.contributor.authorTuğlular, Tülin
dc.contributor.buuauthorAli, Rıdvan
dc.contributor.buuauthorALİ, RIDVAN
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı.
dc.contributor.researcheridGXD-8209-2022
dc.date.accessioned2024-07-05T12:31:15Z
dc.date.available2024-07-05T12:31:15Z
dc.date.issued2020-01-01
dc.description.abstractObjective: This study aimed to evaluate real-life data on patterns of hydroxyurea prescription/use in polycythemia vera (PV).Materials and Methods: This retrospective chart review study included PV patients who had received hydroxyurea therapy for at least 2 months after PV diagnosis. Data were collected from 10 representative academic medical centers.Results: Of 657 patients, 50.9% were in the high-risk group (age 60 years and/or history of thromboembolic event). The median duration of hydroxyurea therapy was 43.40 months for all patients; 70.2% of the patients had ongoing hydroxyurea therapy at last followup. Hydroxyurea was discontinued in 22.4% of the patients; the most common reason was death (38.5%). The predicted time until hydroxyurea discontinuation was 187.8 months (standard error: +/- 21.7) for all patients. This duration was shorter in females (140.3 +/- 37.7 vs. 187.8 +/- 29.7) (p=0.08). This trend was also observed in surviving patients aged >= 50 years at hydroxyurea initiation (122.2 +/- 12.4 vs. 187.8 +/- 30.7, p=0.03). Among the patients who were still on hydroxyurea therapy, 40.3% had a hematocrit concentration of >= 45% at their last followup visit, and the rate of patients with at least one elevated blood cell count was 67.8%.Conclusion: Hydroxyurea prescription patterns and treatment aims are frequently not in accordance with the guideline recommendations. Its discontinuation rate is higher in females.
dc.identifier.doi10.4274/tjh.galenos.2020.2019.0431
dc.identifier.endpage185
dc.identifier.issn1300-7777
dc.identifier.issue3
dc.identifier.startpage177
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2020.2019.0431
dc.identifier.urihttps://hdl.handle.net/11452/42994
dc.identifier.volume37
dc.identifier.wos000564138800005
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherGalenos Yayincilik
dc.relation.journalTurkish Journal Of Hematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectEssential thrombocythemia
dc.subjectPrognostic value
dc.subjectCriteria
dc.subjectHydroxycarbamide
dc.subjectIntolerance
dc.subjectResistance
dc.subjectSurvival
dc.subjectEvents
dc.subjectRisk
dc.subjectEln
dc.subjectPolycythemia vera
dc.subjectHydroxyurea
dc.subjectTreatment outcome
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectHematology
dc.titlePatterns of hydroxyurea prescription and use in routine clinical management of polycythemia vera: A multicenter chart review study
dc.typeReview
dspace.entity.typePublication
relation.isAuthorOfPublication578cac50-ce4d-4818-8e99-2634ef340753
relation.isAuthorOfPublication.latestForDiscovery578cac50-ce4d-4818-8e99-2634ef340753

Files

Collections